SCHEMBL20137035

SCHEMBL20137035

CC(C)(C)OC(=O)COc1cc(Cl)ccc1CN1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 10/20 0.59
VEGFA P15692 1/20 0.52
EGLN1 Q9GZT9 1/20 0.52
ABHD6 Q9BV23 4/20 0.46
PLA2G7 Q13093 3/20 0.46
SETD7 Q8WTS6 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.45
DDR1 Q08345 1/20 0.43
CNR1 P21554 1/20 0.43
TSHR P16473 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
STS P08842 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20158442 0.84 MGLL (0.53) MGLLVEGFAEGLN1ABHD6PLA2G7
SCHEMBL17513187 0.83 VEGFA (0.59) MGLLVEGFAEGLN1ABHD6PLA2G7
SCHEMBL20137138 0.82 VEGFA (0.61) MGLLVEGFAEGLN1ABHD6PLA2G7
SCHEMBL30459413 0.81 MGLL (0.55) MGLLVEGFAEGLN1ABHD6PLA2G7
SCHEMBL20570500 0.81 MGLL (0.55) MGLLVEGFAEGLN1ABHD6PLA2G7
SCHEMBL28382141 0.81 VEGFA (0.51) MGLLVEGFAEGLN1ABHD6PLA2G7
SCHEMBL15093856 0.81 VEGFA (0.57) MGLLVEGFAEGLN1ABHD6PLA2G7
SCHEMBL20971874 0.81 VEGFA (0.57) MGLLVEGFAEGLN1ABHD6PLA2G7
SCHEMBL18917684 0.81 VEGFA (0.59) MGLLVEGFAEGLN1ABHD6PLA2G7
SCHEMBL30902413 0.81 VEGFA (0.54) MGLLVEGFAEGLN1ABHD6PLA2G7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110267963-B MAGL inhibitors H.隆德贝克有限公司 2022-04-01 CN disclosed
EP-3541821-A1 MAGL INHIBITORS Abide Therapeutics, Inc. (US) 2019-09-25 EP disclosed
US-10093635-B2 MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2018-10-09 US disclosed
WO-2018093947-A1 MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-05-24 WO disclosed
WO-2018093947-A1 MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-05-24 WO disclosed
US-20180134674-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-05-17 US disclosed
US-20180134674-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-05-17 US disclosed
US-20180134674-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134674-A1 MAGL INHIBITORS MAG, MAGI3, MGLL MGLL 3/4885VEGFA 4885/4885EGLN1 1615/4885
US-10093635-B2 MAGL inhibitors MAG, MAGI3, MGLL MGLL 3/4885VEGFA 4885/4885EGLN1 1615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.